Satellos Bioscience Inc - MSCLF STOCK NEWS

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) has completed enrollment of all four multiple-ascending dose (MAD) cohorts in its Phase 1 clinical trial of SAT-3247 in healthy volunteers. The company remains on track to report Phase 1a data from both Single-Ascending Dose (SAD) and MAD cohorts in Q1 2025.

The Phase 1b portion of the trial, targeting Duchenne Muscular Dystrophy (DMD) patients, is currently underway with plans to enroll up to 10 adult volunteers with genetically confirmed DMD during Q1 2025. The company also expects to submit its Phase 2 IND filing by the end of Q1 2025.

SAT-3247 is being developed as an oral, once-daily therapy aimed at restoring muscle regeneration and repair in all DMD patients, with potential use as either a standalone or add-on treatment.

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a biotech company focused on developing small molecule therapeutics for muscle diseases, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The virtual conference will take place on February 11-12, 2025.

Co-founder and CEO Frank Gleeson will deliver a corporate presentation on February 11 at 1:20 p.m. ET and will join other management team members in one-on-one meetings throughout the conference. Investors can access the live webcast through the Events and Presentations page in the Investors section of Satellos' website, with a replay available after the presentation.

Bloom Burton & Co has announced changes in its holdings of Satellos Bioscience Inc. The firm acquired 1,692,250 common shares at $0.90 per share, totaling $1,523,025, through a public offering dated December 17, 2024. Despite this acquisition, Bloom Burton's beneficial holdings decreased by approximately 3.7% on a partially diluted basis.

Following the transaction, Bloom Burton, its affiliates, and Brian Bloom now own 10,400,818 shares and 7,528,732 derivative securities, representing approximately 6.3% ownership on a non-diluted basis and 10.3% on a partially diluted basis. Previously, they held 8,708,568 shares and 7,528,732 derivative securities, representing 7.6% non-diluted and 13.3% partially diluted ownership.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) has successfully closed a US$40 million equity offering, issuing 63,285,000 equity securities at $0.90 per common share. The offering consisted of 51,420,000 common shares and 11,865,000 pre-funded common share purchase warrants.

The offering was led by Bloom Burton Securities Inc., alongside Canaccord Genuity Corp., Haywood Securities Inc., and Leede Financial Inc. The net proceeds will fund the company's Phase 2 clinical development of SAT-3247, working capital needs, and general corporate purposes.

Notable insider participation included board member Franklin Berger (320,000 shares), CEO Frank Gleeson (160,000 shares), and Bloom Burton & Co Inc. (1,692,250 shares).

Satellos Bioscience (MSCLF) has announced the pricing of its overnight marketed public offering, aiming to raise up to US$40 million. The offering includes up to 63,285,000 securities at $0.90 per security, consisting of common shares or pre-funded warrants. The warrants can be exercised at a nominal price with no expiration date.

The offering is being conducted through a syndicate led by Bloom Burton Securities, including Canaccord Genuity, Haywood Securities, and Leede Financial. Expected to close around December 20, 2024, the proceeds will fund Phase 2 clinical development of SAT-3247, working capital needs, and general corporate purposes.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) has announced an overnight marketed public offering of common shares and optional pre-funded warrants. The company has filed a preliminary prospectus supplement to its base shelf prospectus dated April 7, 2024, with securities regulatory authorities in British Columbia, Alberta, and Ontario.

The offering will be conducted on a commercially reasonable best efforts basis through Bloom Burton Securities as lead agent. The size, price, and number of securities will be determined through market negotiations. The pre-funded warrants, available at purchasers' discretion, will have a nominal exercise price and no expiration date.

Proceeds will fund Phase 2 clinical development of SAT-3247, working capital needs, and general corporate purposes. The offering is expected to close around December 20, 2024, subject to regulatory approvals.

Satellos Bioscience (OTCQB: MSCLF) has reached a significant milestone in its Phase 1b clinical trial of SAT-3247, with the first Duchenne muscular dystrophy (DMD) participant receiving treatment. The company has successfully completed enrollment of all five single ascending dose (SAD) cohorts and the first two multiple ascending dose (MAD) cohorts in healthy volunteers, with no reported adverse effects.

The Phase 1b trial aims to enroll up to 10 adult participants with genetically confirmed DMD in a 28-day, open-label, single dose study to assess safety and pharmacokinetics. Initial results show SAT-3247 was well-tolerated, with no drug-related adverse events, abnormal clinical findings, or safety concerns. The pharmacokinetic profile successfully translated from pre-clinical models to human subjects. Clinical data is expected to be presented at a major medical conference in Q1 2025.

Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF), a biotech company focused on developing small molecule therapeutics for muscle diseases, announces its participation in Oppenheimer's Movers in Rare Disease Summit in New York City on December 12, 2024. Frank Gleeson, Co-founder and CEO, will participate in a fireside chat titled 'Polypharmacy in DMD and Neuromuscular Disease' at 9:50AM ET. The management team will also be available for one-on-one meetings with registered summit attendees.

Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF) announces participation in a live investor webinar focused on Duchenne muscular dystrophy (DMD) on December 4, 2024, at 2:00 pm ET. The webinar will feature key opinion leaders discussing three main topics: new treatment approaches for DMD, patient navigation of clinical trials, and Satellos' novel small molecule approach focusing on muscle regeneration.

Featured speakers include Elijah Stacy, a DMD patient advocate and Founder of Destroy Duchenne, Dr. Michael Rudnicki, Scientific Founder of Satellos and Director of Regenerative Medicine at Ottawa Hospital Research Institute, and Dr. Jordan Dubow, Satellos' CMO. The event will include a Q&A session and is free to attend.